Genomic medicine in Chagas disease

Acta Trop. 2019 Sep:197:105062. doi: 10.1016/j.actatropica.2019.105062. Epub 2019 Jun 12.

Abstract

Genetic approaches have been proposed for improving the understanding of the causes of differential susceptibility to Trypanosoma cruzi infection and Chagas disease outcome. Polymorphisms in genes involved in the immune/inflammatory response are being studied in order to clarify their possible role in the occurrence or severity of the cardiac and/or gastrointestinal complications. However still today, the number of significant associated genes is limited and the pathophysiological mechanisms underlying this condition are unknown. This article review the information currently available from the published scientific literature regarding the genetic variants of molecules of the immune system and other variants that can contribute to the clinical presentation of the disease. Genomic medicine will improve our knowledge about the molecular basis of Chagas disease, will open new avenues for developing biomarkers of disease progression, new therapeutic strategies to suit the requirements of individual patients, and will contribute to the control of one of the infections with the greatest socio-economic impact in the Americas.

Keywords: Association studies; Genetic risk factors; Neglected tropical disease; Personalized medicine.

Publication types

  • Review

MeSH terms

  • Chagas Disease / drug therapy
  • Chagas Disease / genetics*
  • Disease Progression
  • Genomics
  • Humans
  • Polymorphism, Genetic